NCT03315754View on ClinicalTrials.gov

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

November 2, 2020

Study Completion Date

February 2, 2025

Conditions
Localized Prostate Cancer
Interventions
DRUG

TOOKAD Soluble 4 mg/kg

Vascular targeted photodynamic therapy using TOOKAD Soluble

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Steba Biotech S.A.

OTHER